This page shows the latest tralokinumab news and features for those working in and with pharma, biotech and healthcare.
Prospects for IL-13 inhibitor tralokinumab look terminal after three failed late-stage trials, however, and AZ also has an Amgen-partnered thymic stromal lymphopoietin (TSLP) targeting antibody - tezepelumab - in phase
Prospects for IL-13 inhibitor tralokinumab look rocky after two failed late-stage trials, elevating the importance of Fasenra in those plans.
Benralizumab has assumed much greater importance for the company since IL-13 inhibitor tralokinumab - another severe asthma candidate - failed two phase III trials.
Setback for AZ as tralokinumab flunks asthma trial. Puts more pressure on AZ’s benralizumab to reach its potential. ... Tralokinumab is an inhibitor of interleukin-13 (IL-13), while benralizumab works by blocking the activity of IL-5.
Disappointing results with other IL-13-targeting drugs in asthma - including Pfizer's anrukinzumab and AstraZeneca's tralokinumab - undermined confidence in the approach.
Prospects for drugs targeting interleukin-13 for asthma treatment have taken another knock after AstraZeneca's tralokinumab failed a phase III trial. ... It looks increasingly like a lost cause as AZ already reported disappointing phase IIb data with
More from news
Approximately 4 fully matching, plus 15 partially matching documents found.
Out-partnering deals included the $1.1bn licence to LEO for tralokinumab in skin diseases and the $1bn divestment to Pfizer of its late-stage small molecule anti-infective business.
AstraZeneca is developing tralokinumab for severe asthma, where it is in phase III development, and has recently completed a phase IIb study in patients with atopic dermatitis. ... Acquisition. 1, 530. AstraZeneca/ Leo Pharma. Tralokinumab (anti-IL-13)
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...